#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Pouchitis Primary hyperoxaluria Follicular lymphoma stage II Hypocalcaemia Nephroblastoma Anti-myelin-associated glycoprotein associated polyneuropathy Metastases to peritoneum Autoimmune haemolytic anaemia Idiopathic inflammatory myopathy B-cell small lymphocytic lymphoma recurrent Penile squamous cell carcinoma Hypoparathyroidism Von Hippel-Lindau disease Cystic fibrosis respiratory infection suppression Thrombocytopenia More trials…

    Learn about Rare Diseases

    Factor VIII deficiency – Life with Disease Alport’s syndrome – Diagnostics Friedreich’s ataxia – Treatment Piriformis syndrome – Trials in Disease Carcinoid syndrome – Treatment Congenital generalised lipodystrophy – Diagnostics Mantle cell lymphoma stage II – Treatment Synovial sarcoma – Treatment Brain stem glioma – Trials in Disease Nephrotic syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pitolisant Azd8421 HUMAN PLASMA Lenzumestrocel Avelumab Mexiletine Hydrochloride Gozetotide Alf-18 Remimazolam Peppermint Oil [18F] CANAGLIFLOZIN Teicoplanin Eteplirsen POLYMYXIN B SULFATE DCC-3084 Specific Nucleic Acid Sna-Papi ZODASIRAN Dabigatran Etexilate Dextromethadone Hydrochloride Revumenib Carvedilol More therapies…

    Learn about Your Condition

    Congenital ureteric anomaly Cardiovascular disorder Haemorrhagic stroke Femur fracture Transitional cell carcinoma Oral neoplasm Colorectal cancer stage III Prinzmetal angina Anxiety disorder Cardiac valve disease Pancreatic neoplasm Ankylosing spondylitis Chronic kidney disease Factor VIII deficiency Immune-mediated enterocolitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study on the Safety and Tolerability of OsteoDex for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Osteodex
    Sweden

  • Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Isatuximab
    • Carfilzomib
    • Lenalidomide
    Germany

  • Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate Ph. Eur.
    • Isatuximab
    • Bortezomib
    Czechia Denmark France Germany Greece Italy +5

  • Study on [68Ga]Ga-PentixaFor for Staging and Evaluation in Symptomatic Multiple Myeloma Patients in Initial Treatment or Relapse

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Pentixafor Gallium Ga-68
    France

  • Study on Belantamab Mafodotin with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Daratumumab
    • Dexamethasone
    Greece

  • Study of belantamab mafodotin with bortezomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Belantamab Mafodotin
    • Melphalan
    • Bortezomib
    Spain
Previous Page
1 … 14 15 16 17 18 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!